| Ytd | 82.65% | |
| 1y | 16.23% |
| Open | 1.94 | Prev Close | 1.93 | Low | 1.78 | High | 1.95 | Mkt Cap | 214.48M |
| Vol | 1.38M | Avg Vol | 1.60M | EPS | -1.05 | P/E | N/A | Forward P/E | -0.99 |
| Beta | 1.88 | Short Ratio | 3.10 | Inst. Own | 102.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 2.42 | 200-d Avg | 1.90 | 1yr Est | 6.31 |
FATE News
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweigh
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and r
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and main
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analys
US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Bu
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analys
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus
HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly ear
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Tuesday, 210 companies reached new 52-week lows.
During Monday's session, 201 stocks hit new 52-week lows.
During the Friday's sesion, 157 stocks hit new 52-week lows.
On Thursday, 128 companies set new 52-week lows.
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
During Thursday's session, 92 stocks hit new 52-week lows.
During Wednesday's trading, 103 companies set new 52-week lows.
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for
Tuesday's session saw 325 companies set new 52-week lows.
On Tuesday, 298 companies achieved new lows for the year.
During Friday's trading, 293 companies set new 52-week lows.
On Thursday, 241 companies hit new 52-week lows.
Monday saw 196 companies set new 52-week lows.
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday